On November 3rd, 2016, Inbiose, a Belgium-based producer of specialty carbohydrates and DuPont Nutrition & Health (DuPont, USA) announced a joint development and licensing agreement for exclusive rights to selected fucosylated human milk oligosaccharides (HMOs), including 2’-fucosyllactose.
HMOs are a group of unique oligosaccharides found in mother’s milk, with 2’-fucosyllactose being the single most abundant HMO. HMOs have been identified as important components of human milk that help shape an infant’s gut microbiome and a balanced immune system development. A growing body of evidence suggests that HMOs benefit the health of developing infants by supporting digestive, immune and cognitive development.
Inbiose and Bio Base Europe Pilot Plant have been collaborating since 2013 for the development and scale-up of Inbiose’s technology. During this collaboration, the innovative process has been successfully demonstrated at 1500 L, 4500 L and 15 000 L scale. The downstream process has been optimized and applied at scale as well.
The new partnership combines Inbiose’s innovative production platform for specialty carbohydrates with DuPont’s capabilities in industrial-scale fermentation, regulatory and health science expertise, as well as global market access.
“This partnership is part of a new era in ingredients targeted for infant nutrition,” said John Rea, global business unit leader for Probiotics, Cultures, Food Protection and HMOs. “With this development, we’re working toward fulfilling our corporate mission to help solve the world’s food challenges by providing innovative ingredients our customers can use to make healthy and nutritious products. Our investment here complements the broad capabilities DuPont has built in probiotics and understanding the human gut microbiome, as well as our technologies already targeting this area.”
The partnership is currently focusing on developing the ingredients for market introduction by implementing an industrial-scale fermentation process and submission for regulatory approvals to enter the market in 2017. “We are excited to collaborate with Inbiose and bring the science of HMOs to market,” said Martin Kullen, global R&D leader for Probiotics, Cultures, Food Protection and HMOs. “HMOs are key in helping our customers move another step closer to matching the composition of human milk with their infant nutrition products.”